Argenx
ARGX
#591
Rank
HK$266.26 B
Marketcap
HK$4,382
Share price
-5.41%
Change (1 day)
14.62%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2024 (TTM): -HK$0.5 Billion

According to Argenx 's latest financial reports the company's current earnings are HK$1.85 Billion. In 2023 the company made an earning of -HK$2.38 Billion, an increase over its 2022 earnings that were of -HK$5.68 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -HK$0.5 Billion-79.22%
2023 -HK$2.38 Billion-58.25%
2022 -HK$5.68 Billion
2019 -HK$1.55 Billion124.95%
2018 -HK$0.69 Billion132.04%
2017 -HK$0.3 Billion54.86%
2016 -HK$0.2 Billion33%
2015 -HK$0.15 Billion13.63%
2014 -HK$0.13 Billion46.25%
2013 -HK$86.76 Million